Immunovia invites to a teleconference (in English) for investors, analysts and media on Friday, February 14th, 2020 at 8:30 am CET . Immunovia will publish the company’s Full Year 2019 report on February 14 th , 2020 at 8:00 am CET . Mats Grahn , CEO will present Immunovia and comment on the interim report for the period
| LUND, Sweden, Feb. 10, 2020 /PRNewswire/ -- Immunovia invites to a teleconference (in English) for investors, analysts and media on Friday, February 14th, 2020 at 8:30 am CET. Immunovia will publish the company’s Full Year 2019 report on February 14th, 2020 at 8:00 am CET. Mats Grahn, CEO will present Immunovia and comment on the interim report for the period Full Year 2019 Report followed by a Q&A session. Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator: Dial-in numbers: Sweden: +46-(0)-8-50-520-424 United States: +1-212-999-6659 Austria: +43-(0)-12530807 Germany: +49-(0)-30-3001-90612 Denmark: +45-3271-4573 Switzerland: +41-(0)-22-592-7103 Spain: +34-91-787-0777 Netherlands: +31-(0)-20-794-8426 Norway: +47-2156-3318 France: +33-(0)-1-7037-7166 United Kingdom (standard international access): +44-(0)-20-3003-2666 Conference code: (To provide to the operator): Immunovia Webcast: https://channel.royalcast.com/webcast/immunovia/20200214_1/ There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended. About Immunovia Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”. The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. CONTACT: For more information, please contact: Julie Silber, Director of Investor Relations, Immunovia This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Immunovia AB | ||
Company Codes: Bloomberg:IMMNOV@SS, ISIN:SE0006091997, RICS:IMMNOV.ST, Stockholm:IMMNOV |
View original content:
